Jim Simons Moleculin Biotech, Inc. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.41 - $0.86 $3,853 - $8,084	9,400 Added 7.82%	129,600 $111,000
Q3 2023 Nov 14, 2023	SELL	$0.38 - $0.72 $2,736 - $5,184	-7,200 Reduced 5.65%	120,200 $51,000
Q2 2023 Aug 11, 2023	BUY	$0.54 - $0.95 $17,709 - $31,155	32,795 Added 34.67%	127,400 $74,000
Q1 2023 May 12, 2023	BUY	$0.9 - $1.34 $11,164 - $16,622	12,405 Added 15.09%	94,605 $91,000
Q4 2022 Feb 13, 2023	SELL	$0.85 - $16.65 $1,955 - $38,295	-2,300 Reduced 2.72%	82,200 $87,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $17.4 $4,140 - $62,639	-3,600 Reduced 4.09%	84,500 $90,000
Q2 2022 Aug 12, 2022	BUY	$1.19 - $2.0 $33,558 - $56,400	28,200 Added 47.08%	88,100 $128,000
Q1 2022 May 13, 2022	BUY	$1.23 - $1.9 $32,595 - $50,350	26,500 Added 79.34%	59,900 $107,000
Q4 2021 Feb 11, 2022	BUY	$1.64 - $2.83 $54,776 - $94,522	33,400 New	33,400 $62,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.